VentureBeat

Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...
Nature

The path to destruction for D-type cyclin proteins

Charupong Saengboonmee is in the Department of Cancer Biology, Dana-Farber Cancer Institute, and in the Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02215 ...
JSTOR Daily

Expression of Cyclins E1 and E2 during Mouse Development and in Neoplasia

Yan Geng, Qunyan Yu, Wendy Whoriskey, Fred Dick, Kenneth Y. Tsai, Heide L. Ford, Debajit K. Biswas, Arthur B. Pardee, Bruno Amati, Tyler Jacks, Andrea Richardson, Nicholas Dyson, Piotr Sicinski ...
News Medical

Investigating the role of cyclins and cyclin-dependent kinases in host restriction of SARS-CoV-2 infection

In a recent study posted to the bioRxiv* pre-print server, researchers investigated coronavirus disease 2019 (COVID-19)-triggered changes in the levels of cyclins and cyclin-dependent kinases (CDKs) ...
Business Wire

Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
VentureBeat

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for ...
Morningstar

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program Circle Pharma, Inc., a clinical-stage ...
JSTOR Daily

Cyclins A and B Associate with Chromatin and the Polar Regions of Spindles, Respectively, and Do Not Undergo Complete Degradation at Anaphase in Syncytial Drosophila Embryos

Maternally contributed cyclin A and B proteins are initially distributed uniformly throughout the syncytial Drosophila embryo. As dividing nuclei migrate to the cortex of the embryo, the A and B ...
News Medical

What are Cyclin-Dependent Kinases?

Cyclin-dependent kinases are a type of serine/threonine kinase which are activated by cyclins to drive the progress of the cell cycle. The cell cycle is a comprised of 4 stages, which are tightly ...
ascopubs.org

Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors

Fig 1. Putative mechanisms of resistance to CDK4/6i. Cartoon shows G1 checkpoint kinases CDK4/6 coupled to D-cyclins promoting cell cycle progression through the G1-S transition by phosphorylating Rb ...
Business Wire

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting

“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle Pharma.